Diagnosis and treatment of patients with testicular germ cell cancer

Drugs

Volumn 58, Issue 2, 1999, Pages 257-281

  Hartmann, Jörg T ^a,b   Kanz, Lothar ^a   Bokemeyer, Carsten ^a,b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; SEROTONIN 3 ANTAGONIST; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ANEMIA; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG TOXICITY; GERM CELL TUMOR; GONAD DYSFUNCTION; HISTOPATHOLOGY; HUMAN; LUNG TOXICITY; LYMPHADENECTOMY; MALE; MALE INFERTILITY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; ORCHIECTOMY; OTOTOXICITY; PROGNOSIS; RADIATION DOSE; RAYNAUD PHENOMENON; REVIEW; SEMINOMA; TESTIS CANCER; THROMBOCYTOPENIA; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; GERMINOMA; HUMANS; MALE; NEOPLASM METASTASIS; RECURRENCE; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 0032815295     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958020-00004     Document Type: Review

References (188)

1. 1. Osterlind A. Diverging trends in incidence and mortality of testicular cancer in Denmark, 1943-1982. Br J Cancer 1986; 53: 501-5
2. 2. Hernes EH, Harstad K, Fossa SD. Changing incidence and delay of testicular cancer in southern Norway, 1981-1992. Eur Urol 1992; 30: 349-57
3. 3. Stone J, Cruickshank D, Sandeman T, et al. Trebling of the incidence of testicular cancer in Victoria, Australia 1950-1985. Cancer 1991; 68: 211-9
4. 4. Buetow SA. Epidemiology of testicular cancer. Epidemiol Rev 1995; 17: 433-49
5. 5. Batata M, Chu F, Hilaris B, et al. Testicular cancer in cryptorchids. Cancer 1982; 49: 1023-30
6. 6. Satge D, Sasco AJ, Cure H, et al. An excess of testicular germ cell tumors in Down's syndrome. Cancer 1997; 80: 929-35
7. 7. Dieckmann K-P, Pichlmeier U. The prevalence of familial testicular cancer: an analysis of two patient populations and a review of the literature. Cancer 1997; 80: 1954-60
8. 8. Mostofi FK, Sesterhenn IA. WHO classification of testicular cancer. 2nd ed. Berlin: Springer, 1998
9. 9. Jacobsen G, Henriksen OB, von der Maase H. Carcinoma in situ of testicular tissue adjacent to malignant germ-cell tumors: a study of 105 cases. Cancer 1981; 47 (11): 2660-2
10. 10. Dieckmann KP, Loy V. Prevalence of contralaleral testicular intraepithelial neoplasia in patients with germ cell neoplasia. J Clin Oncol 1996; 14: 3126-32
11. 11. Pryor JP, Cameron KM, Chilton CT, et al. Carcinoma in situ in testicular biopsies from men presenting with infertility. Br J Urol 1983; 55: 780-4
12. 12 Chaganti RS, Rodriguez E, Bosl GJ. Cytogenetics of male germ cell tumors. Urol Clin North Am 1993; 20: 55-66
13. 13. Rodriguez E, Mathew S, Reuter V, et al. Cytogenetic analysis of 124 prospectively ascertained male germ cell tumors. Cancer Res 1992; 52: 2285-91
14. 14. Bosl GJ, Ilson DH, Rodriguez E, et al. Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 1994; 86: 349-55
15. 15. Mostert MMC, van de Pol M, Olde-Weghuis D, et al. Comparative genomic hybridization of germ cell tumors of the adult testis: confirmation of karyotypic findings and identification of a 12p-amplicon. Cancer Genet Cytogenet 1996; 89: 146-52
16. 16. Vos A, Oosterhuis W, de Jong B, et al. Cytogenetics of carcinoma in situ of the testis. Cancer Genet Cytogenet 1990; 46: 75-81
17. 17. Manivel J, Jessurun J, Wick M, et al. Placental alkaline phosphatase immunoreactivity in testicular germ-cell neoplasms. Am J Surg Pathol 1987; 11: 21-9
18. 18. Cavalli F, Monfardini S, Pizzocaro G. Report on the international workshop on staging and treatment of testicular cancer. Eur J Cancer 1980; 16: 1367-72
19. 19. Fleming ID, editor. Testis. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven, 1997: 225-30
20. 20. Mead GM, Stenning SP, Cook P, et al. International germ cell consensus classification: a prognostic factor-erased staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603
21. 21. Fossa S, Aass N, Kaalhus O. Radiotherapy for testicular seminoma stage I: treatment results and long-term post-irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 1989; 16: 383-8
22. 22. Zagars GK, Babaian RJ. Stage I testicular seminoma: rationale for postorchidectomy radiation therapy. Int J Radiat Oncol Biol Phys 1987; 13: 155-62
23. 23. van Leeuwen F, Stiggelbout A, van den Belt-Dusebout A, et al. Second cancer risk following testicular cancer: a follow up study of 1,909 patients. J Clin Oncol 1993; 11: 415-24
24. 24. Warde P, von der Maase H, Norwich A, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance [abstract 1188]. Proc Am Soc Clin Oncol 1998; 17: 309a
25. 25. Donohue JP, Thornhill JA, Foster RS, et al. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer: review of the Indiana University experience 1965-1989. Br J Urol 1993; 71: 326-35
26. 26. Pizzocaro G. Rationale for lymphadenectomy in stage I non-seminoma. In: Horwich A, editor. Testicular cancer. 2nd ed. London: Chapman and Hall Medical, 1996: 193-200
27. 27. McLeod DG, Weiss RB, Stablein DM, et al. Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol 1991; 145: 1178-83
28. 28 Donohue JP, Thornhill JA, Foster-RS, et al. Stage 1 non-seminomatous germ-cell testicular cancer management options and risk-benefit considerations. World J Urol 1994; 12: 170-6
29. 29. Droz JP, van Oosterom AT. Treatment options in clinical stage I non-seminomatous germ cell tumours of the testis: a wager on the future? A review. Eur J Cancer 1993; 29A: 1038-44
30. 30. Sesterhenn IA, Weiss RB, Mostofi FK, et al. Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma: a report from the Testicular Cancer Intergroup Study. J Clin Oncol 1992; 10 (1): 69-78
31. 31. Donohue JP, Zachary JM, Maynard BR. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 1982; 128: 315-20
32. 32. Raghavan D, Vogelzang NJ, Bosl GJ, et al. Tumor classification and size in germ-cell testicular cancer: influence on the occurrence of metastases. Cancer 1982; 50: 1591-5
33. 33. Donohue JP, Foster RS, Rowland RG, et al. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 1990; 144: 287-91
34. 34. Peckham MJ, Barrett A, Husband JE, et al. Orchiectomy alone in testicular stage I nonseminomatous germ cell tumors. Lancet 1982; II (8300); 678-80
35. 35. Bokemeyer C, Schmoll H-J, Kuczyk MA, et al. Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J Natl Cancer Inst 1995; 87: 58-60
36. 36. Freedman LS, Parkinson MC, Jones WG, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchiectomy alone. Lancet 1987; II (8554): 294-8
37. 37. Cullen MH, Stenning SP, Parkinson MC, et al. Short course adjuvant chemotherapy in high risk stage I non-seminomatous germ cell tumours of the testis: a Medical Research Council report. J Clin Oncol 1996; 14: 1106-13
38. 38. Pont J, Albrecht W, Postner G, et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996; 14: 441-8
39. 39. Bokemeyer C, Kuezyk MA, Serth J, et al. Treatment of clinical stage I testicular and cancer and the possible role for new biological prognostic parameters. J Clin Oncol Res Clin Oncol 1996; 122: 575-84
40. 40. Albers P, Bicrhoff E, Neu D, et al. MIB-I immunohistochemistry in clinical stage I nonserminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer 1997; 79: 1710-6
41. 41. Leibovitch I, Foster RS, Kopecky KK, et al. Identification of clinical stage a nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitative immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol 1998; 16: 261-8
42. 42. Schmidberger H, Bamberg M, Meisner C, et al. Radiotherapy in Stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int J Radiat Oncol Biol Phys 1997; 39: 321-6
43. 43. Motzer RJ, Sheinfeld J, Mazumdar M, et al. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol 1995; 13: 2700-4
44. 44. Williams SD, Stablein DM, Einhorn LH, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987; 317: 1433-8
45. 45. Albers P, Albers J, Cummings OW, et al. Flow cytometric and cytophotometric DNA analysis cannot predict subsequent tumour recurrence in pathological stage IIA/B non-seminomatous testicular germ cell tumour patients who do not receive adjuvant chemotherapy [letter]. Eur J Cancer 1995; 31A: 848-9
46. 46. Willan B, McGowan D. Seminoma of the testis: a 22-year experience with radiation therapy. Int J Radial Oncol Biol Phys 1985; 11: 1769-75
47. 47. Gregory C, Peckham M. Results of radiotherapy for stage II testicular seminoma. Radiother Oncol 1986; 6: 285-92
48. 48. Fossa SD, Droz JP, Stoter G, et al. Cisplatin, vineristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group. Br J Cancer 1995; 71: 619-24
49. 49. Logothetis CJ, Samuels ML, Ogden SL, et al. Cyclophosphamide and sequential cisplatin for advanced seminoma: long-term follow up in 52 patients. J Urol 1987; 138: 789-94
50. 50. Pizzocaro G, Salvioni R, Piva L, et al. Cisplatin combination chemotherapy in advanced seminoma. Cancer 1986; 58: 1625-9
51. 51. Schmoll HJ, Harstrick A, Bokemeyer C, et al. Single-agent carboplatinum for advanced seminoma: a phase II study. Cancer 1993; 72: 237-42
52. 52. Mencel PJ, Motzer RJ, Mazumdar M, et al. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994; 12: 120-6
53. 53. Horwich A, Dearnaley DP, A'Hern R, et al. The activity of single-agent carboplatin in advanced seminoma. Eur J Cancer 1992; 28A: 1307-10
54. 54. Sleijfer S, Willemse PHB, deVries EGE, et al. Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis. Br J Cancer 1996; 74: 947-50
55. 55. Jones DM, Amato LC, Pagliari R, et al. Carboplatin (CBDCA) and cyclophosphamide (CTX) and delayed consolidation in advanced seminoma [abstract 1149]. Proc Am Soc Clin Oncol 1997; 16: 323a
56. 56. Fossa SD, Borge L, Ass N, et al. The treatment of advanced metastatic seminoma: experience in 55 cases. J Clin Oncol 1987; 5: 1071-7
57. 57. Loehrer PJ, Birch R, Williams SD, et al. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 1987; 5: 1212-20
58. 58. Clemm C, Gerl A, Hentrich M, et al. Chemotherapy for far advanced seminoma [abstract 909]. Onkologie 1995; 18: 189
59. 59. Horwich A, Paluchowska B, Normann A, et al. Residual mass following chemotherapy of seminoma. Ann Oncol 1997; 8: 37-40
60. 60. Bosl GJ, Geller NL, Cirricione C, et al. Multivariate analysis of prognostic variables in patients with metastatic cancer. Cancer Res 1983; 43: 3403-4
61. 61. Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomised trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993; 11: 598-606
62. 62. Horwich A, Oliver RTD, Fossa SD, et al. A randomised MRC trial comparing single agent carboplatin with the combination of etoposide, and cisplatin in patients with advanced metastatic seminoma [abstract no. 668]. Proc Am Soc Clin Oncol 1996; 15: 258
63. 63. Williams S, Birch R, Einhorn LH, et al. Treatment of disseminated germ cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-40
64. 64. Birch R, Williams S, Cone A, et al. Prognostic factors for favourable outcome in disseminated germ cell tumors. J Clin Oncol 1986; 4: 400-7
65. 65. Saxman SB, Finch D, Gonin R, et al. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indiana University experience. J Clin Oncol 1998; 15: 702-6
66. 66. Loehrer Sr PJ, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors; an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995; 13: 470-6
67. 67. Xiao H, Mazumdar M, Bajorin DF, et al. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol 1997; 15: 2553-8
68. 68. de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997; 15: 1837-43
69. 69. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide and carboplatin in good-prognosis metastatic nonseminomatous germ cell canter: a Multi-institutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 1997; 15: 1844-52
70. 70. Bokemeyer C, Köhrmann O, Tischler J, et al. A randomized trial of cisplatin. etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumours. Ann Oncol 1996; 7: 1015-21
71. 71. Bosl GJ, Geller NL, Bajorin D, et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumor. J Clin Oncol 1988; 6: 1231-8
72. 72 Harstrick A, Caspar J, Guba R, et al. Comparison of the antitumor activity of cisplatin, carboplatin and iproplatin against established human testicular canter cell lines in vivo and in vitro. Cancer 1989; 63: 1079-83
73. 73. De Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998; 78: 828-32
74. 74. de Wit R, Louwerens M, Mulder PMH, et al. A dose finding study of paclitaxel added to fixed doses of bleomycin, etoposide, cisplatia (BEP) in patients with adverse prognosis germ cell cancer or cancer of unknown primary (CUP) [abstract 1240]. Proc Am Soc Clin Oneol 1998; 17: 322a
75. 75. Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/ European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998: 16: 692-701
76. 76. de Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 1995; 71: 1311-4
77. 77. Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia group B study. J Clin Oncol 1998; 16: 1287-93
78. 78. Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991; 7: 1163-72
79. 79. Wozmak AJ, Samson MK, Shah NT, et al. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. J Clin Oncol 1991; 9: 70-6
80. 80. Ozols RF, Ihde DC, Linchan WM, et al. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 1988; 6: 1031-40
81. 81. Schmoll HJ. The role of ifosfamide in testicular cancer. Semin Oncol 1989; 16 (1 Suppl. 3): 82-95
82. 82. Blijham G. The treatment of advanced testicular carcinoma with high dose chemotherapy and autologous marrow support. Eur J Cancer Clin Oncol 1981; 17: 433-41
83. 83. Wolff SN, Johnson DH, Hainsworth JD, et al. High dose VP-16-213 monotherapy for refractory germinal malignancies: a phase II study. J Clin Oncol 1984; 4: 271-4
84. 84. Mulder POM, de Vries EG, Koops HS, et al. Chemotherapy with maximally tolerable doses of VP-16-123 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors. Eur J Cancer Clin Oncol 1988; 24: 675-9
85. 85. Chevreau C, Droz JP, Pico JC, et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumors. Eur Urol 1993; 23: 213-8
86. 86. Bokemeyer C, Harstrick A, Beyer C, et al. The use of dose-intensified chemotherapy in the treatment of metastatic non-seminomatous testicular germ eell tumors. Semin Oncol 1998; 25 (4 Suppl.): 24-32
87. 87. Steyerberg EW, Keizer HJ, Stoter G, et al. Predictors of residual mass histology following chemotherapy for metastatic non-seminomatous testicular cancer: a quantitative overview of 996 resections. Eur J Cancer 1994; 30: 1231-9
88. 88. Hartmann JT, Schmoll H-J, Kuczyk MA, et al. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol 1997; 8: 531-8
89. 89. Logothetis CJ, Samuels ML, Trindade A, et al. The growing teratoma syndrome. Cancer 1982; 50: 1629-35
90. 90. Molenaar WM, Oosterhuis JW, Meiring A, et al. Histology and DNA contents of a secondary malignancy arising in a mature residual lesion six years after chemotherapy for a disseminated nonseminomatous testicular tumor. Cancer 1986; 58: 264-8
91. 91. Ahlgren AD, Simrell CR, Triche TJ, et al. Sarcoma arising in a residual testicular teratoma after cytoreductive chemotherapy. Cancer 1984; 54: 2015-18
92. 92. Einhorn L, Williams S, Mandelbaum I, et al. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 1981; 48: 904-8
93. 93. Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995; 13: 1177-87
94. 94. Steyerberg EW, Gerl A, Fossa SD, et al. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol 1998; 16: 269-74
95. 95. Toner GC, Panicek DM, Heclan RT, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990; 8: 1683-94
96. 96. Fox E, Weathers T, Williams S, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 1993; 11: 1294-9
97. 97. Hendry WF, A'Hern RP, Hetherington JW, et al. Para-aortic lymphadenectomy after chemotherapy for metastatic nonseminomatous germ cell tumours: prognostic value and therapeutic benefit. Br J Urol 1993; 71: 208-3
98. 98. Fossa SD, Ous S, Lien HH, et al. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 1989; 141: 557-9
99. 99. Mulders PFA, Oosterhoff GON, Boetse C, et al. The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. Br J Urol 1990; 66: 425-9
100. 100. Gerl A, Clemm C, Schmeller N, et al. Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol 1995; 6: 483-8
101. 101. Steyerberg EW, Keizer HJ, Zwartendijk J, et al. Prognosis after resection of residual masses following chemotherapy for metastatic nonseminomatous testicular cancer: a multivariate analysis. Br J Cancer 1993; 68: 195-200
102. 102. Tait D, Peckham MJ, Hendry WF, et al. Post-chemotherapy surgery in advanced non-seminomatous germ-cell testicular tumours: the significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer 1984; 50: 601-9
103. 103. Donohue JP, Fox EP, Williams SD, et al. Persistent cancer in postchemotherapy retroperitoneal lymph-node dissection: outcome analysis. World J Urol 1994; 12: 190-5
104. 104. Fizazi K, Ragan D, Bokemeyer C, et al. Viable malignant cells after primary chemotherapy for metastatic non-seminomatous germ-cell tumors (NSGCT): results from an international study [abstract no. 1183]. Proc Am Soc Clin Oncol 1999; 18: 308a
105. 105. Gerl A, Clemm C, Schmeller N, et al. Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Br J Cancer 1994; 70: 960-5
106. 106. Brenner PC, Harry W, Morse MJ, et al. Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol 1996; 14: 1765-9
107. 107. Tiffany P, Morse MJ, Bosl G, et al. Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumours. Cancer 1986; 57: 978-83
108. 108. Qvist HL, Fossa SD, Ous S, et al. Post-chemotherapy tumour residuals in patients with advanced nonseminomatous testicular cancer: is it necessary to resect all residual masses? J Urol 1991; 145: 300-3
109. 109. Mandelbaum I, Yaw PB, Einhorn LH, et al. The importance of one-stage median sternotomy and retroperitoneal node dissection in disseminated testicular cancer. Ann Thorac Surg 1983; 36: 524-8
110. 110. Hartmann JT, Candelaria M, Kuczyk MA, et al. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 1997; 33: 843-7
111. 111. Coogan CL, Hejase MJ, Wahle GR, et al. Nerve sparing postchemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 1996; 156: 1656-8
112. 112. Stephens WS, Gonin R, Hutchins GD, et al. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumour patients. J Clin Oncol 1996; 14: 1637-41
113. 113. Ellison M, Mostofi F, Flanigan R. Treatment of the residual retroperitoneal mass after chemotherapy for advanced seminoma. J Urol 1988; 140: 618-20
114. 114. Herr HW, Sheinfeld J, Pue HS, et al. Surgery tor a post-chemotherapy residual mass in seminoma. J Urol 1997; 157: 860-2
115. 115. Puc HS, Heclan R, Mazumdan M, et al. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan Kettering Cancer Center. J Clin Oncol 1996; 14: 454-60
116. 116. Duchesne GM, Stenning SP, Aass N, et al. Radiotherapy after chemotherapy for metastatic seminoma - a diminishing role. MRC Testicular Tumour Working Party. Eur J Cancer 1997; 33: 829-35
117. 117. Nichols CR, Roth BJ, Loehrer PJ, et al. Salvage chemotherapy for recurrent germ cell cancer. Semin Oncol 1994; 25 (5 Suppl. 12): 102-8
118. 118. Harstrick A, Schmoll HJ, Wilke H, et al. Cisplatin, etoposide and ifosfamide salvage therapy for refractory or relapsed germ cell carcinoma. J Clin Oncol 1991; 9: 1549-55
119. 119. Motzer RJ, Bajorin DF, Bosl GJ, et al. Paclitaxel (T) containing first-line salvage therapy selected by risk for patients (pts) with germ cell tumors (GCT) [abstract no. 1146]. Proc Am Soc Clin Oncol 1997; 16: 322a
120. 120. Motzer RJ, Cooper K, Geller NL, et al. The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. Cancer 1990; 66: 2476-81
121. 121. Bosl GJ, Yagoda A, Golbey RB, et al. Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors. Am J Med 1985; 78: 423-8
122. 122. Hainsworth JD, Williams SD, Einhorn LH, et al. Successful treatment of resistant germinal neoplasms with VP-16 and cisplatin: results of a Southeastern Cancer Study Group trial. J Clin Oncol 1985; 3: 666-71
123. 123. Pizzocaro G, Pasi M, Salvioni R, et al. Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreatcd germ cell testicular cancer. Cancer 1985; 56: 2399-403
124. 124. Loehrer PJ, Lauer R, Roth BJ, et al. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988; 109: 540-6
125. 125. Josefsen D, Ous S, Hoie J, et al. Salvage treatment in male patients with germ cell tumours. Br J Cancer 1993; 67: 568-72
126. 126. Ledermann JA, Holden L, Newlands ES, et al. The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours. Br J Urol 1994; 74: 225-30
127. 127. Gerl A, Clemm C, Schmeller N, et al. Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer 1995; 72: 1026-32
128. 128. Farhat F, Culine S, Theodore C, et al. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience. Cancer 1996; 77: 1193-7
129. 129. McCaffrey JA, Mazumdar M, Bajorin DF, et al. Ifosfamide-and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 1997; 15: 2559-63
130. 130. Loehrer PJ, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell rumor. J Clin Oncol 1998; 16: 2500-4
131. 131. Nichols CR, Tricot G, Williams S, et al. Dose-intensive chemotherapy in refractory germ cell cancer: a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7: 932-9
132. 132. Broun ER, Nichols CR, Kneebone P, et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992; 117: 124-8
133. 133. Linkesch W, Krainer M, Wagner A. Phase I/II trial of ultrahigh carboplatin, etoposide, cyclophosphamide with ABMT in refractory or relapsed non-seminomatous germ cell tumors (NSGCT) [abstract no. 600]. Proc Am Soc Clin Oncol 1992; 11: 196
134. 134. Broun ER, Nichols CR, Mandanas R, et al. Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors. Bone Marrow Transplant 1995; 16: 353-8
135. 135. Motzer RJ, Gulati SC, Crown JP, et al. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 1992; 69: 550-6
136. 136. Motzer RJ, Mazumdar M, Subhash CG, et al. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993; 85: 1828-35
137. 137. Rosti G, Albertazzi L, Salioni R, et al. High-dose chemotherapy supported with autologous bone marrow transplantation (ABMT) in germ cell tumors: a phase two study. Ann Oncol 1992; 3: 809-12
138. 138. Margolin K, Doroshow JH, Ahn C, et al. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support. J Clin Oncol 1996; 14: 2631-37
139. 139. Motzer RJ, Mazumdar M, Bosl GJ, et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 1996; 14: 1098-105
140. 140. Siegert W, Beyer J, Strohscheer I, German Testicular Cancer Cooperative Study Group, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. J Clin Oncol 1994; 12: 1223-31
141. 141. Beyer J, Kingreen D, Krause M, et al. Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy. Cancer 1997; 79: 161-8
142. 142. Lampe H, Dearnaley DP, Price A, et al. High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours: Eur J Cancer 1995; 31A: 717-23
143. 143. Droz JP, Kramar A, Pico JL. Prediction of long-term response after high-dose chemotherapy with autologous bone marrow transplantation in the salvage treatment of non-seminomatous germ cell tumours. Eur J Cancer 1993; 29A: 818-21
144. 144. Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996; 14: 2638-45
145. 145. Murphy B, Breeden E, Donohue J, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993; 11: 324-9
146. 146. Wood D, Herr H, Motzer R, et al. Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. Cancer 1992; 70: 2354-7
147. 147. Baniel J, Foster RS, Gonin R, et al. Late relapse of testicular cancer. J Clin Oncol 1995; 13: 1170-6
148. 148. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273-9
149. 149. Rowinsky EK, Gilbert MR, McGuire WP, et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991; 9: 1692-703
150. 150. Dunn TA, Grunwald V, Bokemeyer C, et al. Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts. Invest New Drugs 1997; 15: 91-8
151. 151. Bokemeyer C, Schmoll HJ, Natt F, et al. Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J Cancer Res Clin Oncol 1994; 120: 754-57
152. 152. Motzer RJ, Bajorin DF, Schwartz LH, et al. Phase II trial of pachtaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994; 12: 2277-83
153. 153. Bokemeyer C, Beyer J, Rüther U, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996; 7: 31-4
154. 154. Sandler AB, Christou A, Fox S, et al. A phase II trial of paclitaxel in refractory germ cell neoplasms. Cancer 1998; 82: 1381-6
155. 155. Partyka S, Hutchinson L, Amato R. Preliminary results of taxol/cisplatin chemotherapy in patients with refractory or relapsed nonseminomatous germ cell tumor [abstract no. 1161]. Proc Am Assoc Cancer Res 1996; 37: 169
156. 156. Beyer J, Bokemeyer C, Rick O, et al. Salvage treatment in germ-cell tumors using taxol, ifosfamide, cisplatin (TIP) followed by high-dose carboplatin, etoposide and thiotepa (HDCET): first results [abstract no. 1242]. Proc Am Soc Clin Oncol 1998; 17: 322a
157. 157. Bokemeyer C, Hartmann JT, Kuczyk MA, et al. The role of pactitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors. World J Urol 1998; 16: 155-62
158. 158. Bokemeyer C, Gerl A, Schöffski, et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 1999; 17: 512-6
159. 159. Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995; 332: 1-5
160. 160. Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 1985; 56: 2765-70
161. 161. Bosl GJ, Leitner SP, Atlas SA, et al. Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. J Clin Oncol 1986; 4: 1684-9
162. 162. Bokemeyer C, Hartmann JT, Fels L, et al. Amifostine protects against early cisplatin-induced renal damage and enhances CD 34+-cell numbers for PBSC-collection [abstract no. 166]. Proc Am Soc Clin Oncol 1997; 16: 47a
163. 163. Bokemeyer C, Fels LM, Dunn T, et al. Silibinin protects against cisplatin-induced nephrotoxicily without compromising cisplatin or ifosfamide anti-tumor activity. Br J Cancer 1996; 74: 2036-41
164. 164. Hartmann JT, Kollmannsberger C, Kanz L, et al. Platinum organ toxicity and possible prevention in patients with testicular cancer. In J Cancer. In press
165. 165. Bokemeyer C, Kuczyk MA, Kohne H, et al. Haematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy. Ann Hematol 1996; 72: 1-9
166. 166. Fossa SD, Kaye SB, Mead GM, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. J Clin Oncol 1998; 16: 716-24
167. 167. Bokemeyer C, Berger CC, Kuczyk MA, et al. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996; 14: 2923-32
168. 168. Boyer M, Raghavan D, Harris PJ, et al. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 1990; 8: 21-6
169. 169. Osanto S, Bukman A, Van Hoek F, et al. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992; 10: 574-9
170. 170. Roth BJ, Einhorn LH, Greist A. Long-term complications of cisplatin-based chemotherapy for testis cancer. Semin Oncol 1988; 15: 345-50
171. 171. Bokemeyer C, Schmoll HJ. Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 1995; 13: 283-92
172. 172. Berger CC, Bokemeyer C, Schneider M, et al. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 1995; 31: 2229-38
173. 173. Boyer M, Raghavan D. Toxicity of treatment of germ cell tumors. Semin Oncol 1992; 2: 128-42
174. 174. Vogelzang NJ, Bosl GJ, Johnson K. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981; 95: 288-92
175. 175. Berger CC, Bokemeyer C, Schuppert F, et al. Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 1996; 73: 1108-14
176. 176. Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998; 77: 1355-62
177. 177. Gietema JA, Sleijfer DTh, Willemse PHB, et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992; 116: 709-15
178. 178. Lampe H, Horwich A, Norman A, et al. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 1997; 15: 239-45
179. 179. Leitner SP, Bosl GJ, Bajorunas D. Gonadal dysfunction in patients treated for metastatic germ-cell tumors. J Clin Oncol 1986; 4: 1500-5
180. 150. Hartmann JT, Schmoll H-J, Albrecht C, et al. Long-term effects on sexual functioning and fertility after treatment of testicular cancer. Br J Cancer 1999; 80: 801-7
181. 151. Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997; 89: 1429-39
182. 182. Bujorin DF, Motzer RJ, Rodriquez E, et al. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 1993; 85: 60-2
183. 183. Nichols CR, Breeden ES, Loehrer PJ. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 1993; 85: 36-40
184. 184. Pedersen-Bjergaard J, Daugaard G, Hansen ST, et al. Increased risk of myelodysplasia and leukemia after etoposide, cisplatin, and bleomycin for germ-cell tumors. Lancet 1991; 338 (8763): 359-63
185. 185. Kollmannsberger C, Beyer J, Droz J-P, et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998; 16: 3386-91
186. 186. Hartmann JT, Nichols CR, Droz JP, et al. Extragonadal germ cell tumors (EGGCT) and hematological disorders: incidence and outcome from an international database [abstract no. 268]. Ann Oncol 1998; 9 (4 Suppl.): 56
187. 187. Bokemeyer C, Schmoll HJ. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 1993; 11: 1703-9
188. 188. Kollmannsberger C, Hartmann JT, Kanz L, et al. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol 1998; 124: 207-14